Postpartum Screening of Type 2 Diabetes (Tot ou tard)
Gestational diabetes mellitus (GDM) complicates 5 to 30 % of pregnancies. GDM is defined as hyperglycemia with onset or first recognition during pregnancy. Because it is a forerunner of type 2 diabetes mellitus (T2DM), professional associations recommend T2DM postpartum screening (T2DM-pPS) at 6 weeks/6 months post delivery, using a 75g oral glucose tolerance test (OGTT).
However, less than a quarter of these women are screened. This recommendation has failed for multiple reasons; the most important being that busy new mothers must deal with the major inconveniences of returning to a sampling center for a 2h testing session, bringing baby along or paying for a sitter, transportation, parking… A mother-friendly solution is direly needed.
The investigators hypothesize that, in these women, results of an OGTT performed after delivery on the last day of their hospital stay (OGTT-1) will predict results of the recommended OGTT (OGTT-2) at 6 weeks/6 months postpartum.
The main aim of our project is to determine the optimal cut-off value for the 2h glucose result during OGTT-1 in order to predict abnormal glucose tolerance status at OGTT-2 (the gold standard), in the same woman.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Can we Screen Type 2 Diabetes on the 2nd Day After Delivery in Women Who Had Gestational Diabetes Mellitus?|
- Diagnosis of abnormal glucose tolerance [ Time Frame: 12 weeks postpartum ]Oral glucose tolerance test
- Patient's satisfaction [ Time Frame: 12 weeks post-partum ]Satisfaction questionnaire
|Study Start Date:||April 2014|
|Estimated Study Completion Date:||December 2017|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Experimental: postpartum screening
Oral glucose tolerance test 2 days post-partum
Procedure: oral glucose tolerance test 2 days post-partum
Screening for type 2 diabetes after gestational diabetes mellitus.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01869608
|Clinical Research Center Étienne-Le Bel of the Sherbrooke University Hospital|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Principal Investigator:||Jean-Luc Ardilouze, MD, PhD||Clinical Research Center Étienne-Le Bel of the Sherbrooke University Hospital|